A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Sponsor
Boehringer Ingelheim
Study ID
NCT03817463
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

Key Dates

First listed
Jan 25, 2019
Start date
Apr 15, 2019
Status verified
May 2024
Primary completion
Dec 10, 2021
Completion
Dec 10, 2021

Study Design

Enrollment
327,624 participants (actual)

Arms

  • Arm: New users of SGLT-2i
    Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i) including empagliflozin.
  • Arm: New users of DPP-4i
    Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i).

Primary Outcome Measure

Number of Participants With Hospitalization for Heart Failure (HHF), Broad + Specific Definition [ Time Frame: From index date until end of follow-up, up to 67 months for matched cohort of empagliflozin/DPP-4i. Up to 86 months for matched cohort of SGLT-2i/DPP-4i ]

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies